# Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

> **NCT00049569** · NA · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 126 (estimated)

## Conditions studied

- L1 Childhood Acute Lymphoblastic Leukemia
- L2 Childhood Acute Lymphoblastic Leukemia
- Non-T, Non-B Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- T-cell Childhood Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** cytarabine
- **DRUG:** methotrexate
- **DRUG:** vincristine sulfate
- **DRUG:** prednisone
- **DRUG:** pegaspargase
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** imatinib mesylate
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **BIOLOGICAL:** filgrastim
- **DRUG:** leucovorin calcium
- **DRUG:** asparaginase
- **DRUG:** therapeutic hydrocortisone

## Key facts

- **NCT ID:** NCT00049569
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049569, "Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00049569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*